Atopic Dermatitis

Educational interventions for patients, including both in-person and online methods, significantly reduced atopic dermatitis (AD) severity.

Patients with atopic dermatitis (AD) may have an increased risk of headache disorder and migraines.

A meta-analysis found significant associations between maternal stress, anxiety, depression, and adverse life events during pregnancy with increased atopic dermatitis (AD) risk in offspring.

Children with atopic dermatitis (AD) face higher chances of learning and memory difficulties, particularly when they have neurodevelopmental comorbidities, like attention-deficit/hyperactivity disorder.

A considerable number of patients with atopic dermatitis (AD) and limited health literacy, especially older individuals, experienced impaired health-related quality of life.

This study enhances current understandings of dupilumab use in patients with atopic dermatitis (AD) by showing its real-world effectiveness and safety.

Adult patients with moderate to severe atopic dermatitis (AD) had a 1-year and 1.5-year upadacitinib drug survival of 91.5% and 80.2%, respectively.

This systemic review determined telemedicine to be as effective as in-person appointments for the follow-up of patients with atopic dermatitis (AD).

Although injection site reactions were common occurrences in both the tralokinumab and dupilumab groups, tralokinumab caused ISRs more frequently.

Dupilumab and topical corticosteroids can be used to treat symptoms in children with atopic dermatitis (AD).

Global warming, wildfires, precipitation, floods, and storms impact patients with atopic dermatitis (AD).

The researchers suggested that physicians consider age-relevant atopic dermatitis (AD) treatment preferences in discussions with patients and caregivers.

This study suggests that adolescents with atopic dermatitis (AD) sleep less, have greater sleep dissatisfaction, and longer weekend catch-up sleep (WCUS) than those without AD.

Andy Blauvelt, MD, MBA, president of Oregon Medical Research Center, recommends new novel topical therapies over topical steroids for patients with atopic dermatitis (AD).

Elaine Siegfried, MD, of Saint Louis University School of Medicine, discusses how the recent guideline update by the American Academy of Dermatology (AAD) affects dermatologists' atopic dermatitis (AD) treatment decisions.

This year’s most-read articles on atopic dermatitis (AD) explored different treatment and education methods.

Understanding these relationships is crucial for developing effective clinical management strategies for patients with AD, according to a recent literature review.

Our top coverage from this year’s Revolutionizing Atopic Dermatitis (RAD) conference highlighted the evolving therapy landscape for patients with AD.

Elaine Siegfried, MD, of Saint Louis University School of Medicine discusses the use of biologics to treat atopic dermatitis (AD) and how they differ from other treatments.

Of patients in the atopic dermatitis (AD) cohort, 36.6% developed at least 1 comorbidity amid follow-up compared to 28.5% in the non-AD reference cohort.

Based on the Likert scale, most patients with atopic dermatitis (AD) using baricitinib reported being either “satisfied” (76%) or “very satisfied” (18%).

A new study presented at this year’s American College of Allergy, Asthma and Immunology Annual Scientific Meeting highlights the need for mental health support in patients with atopic dermatitis (AD).

These new atopic dermatitis (AD) treatment guidelines from the American Academy of Dermatology (AAD) update their 2014 recommendations for the management of AD with phototherapy and systemic therapies.

With the recent development of various new treatments, April Armstrong, MD, MPH, discusses the new standards she and other dermatologists hope to set for treating patients with atopic dermatitis (AD).

The results from this 5-year, open-label extension trial affirm the safety of dupilumab in adults with moderate to severe AD.

Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at Northwestern University's Feinberg School of Medicine, describes different methods dermatologists can use to treat atopic dermatitis (AD).

Because of their study's findings, the researchers urged clinicians to screen patients with atopic dermatitis (AD) for cognitive dysfunction.

April Armstrong, MD, MPH, of University of California, Los Angeles, discussed how recent biologics advancements improved moderate-to-severe atopic dermatitis (AD) treatment.

The most common conditions or concerns patients with atopic dermatitis (AD) reported having that may influence their selection of a JAK inhibitor included an increased risk of MACE and an age above 65 years.

April Armstrong, MD, MPH, of University of California, Los Angeles, gave an overview of her Fall Clinical Dermatology session on treating atopic dermatitis (AD) in patients with diverse skin tones and weighed in on how to address related treatment barriers.